Skip to main content

Research-informed explainer · Last reviewed April 12, 2026

5 signs your skin rash needs a dermatologist

Skin rash not improving with OTC cream? Learn 5 warning signs that mean it's time to see a dermatologist, not reach for another tube of cortisone.

Research-informed explainer — last updated April 12, 2026

Most skin rashes do clear up on their own or with a basic OTC cream. But five specific warning signs mean you should skip the drugstore aisle and call a dermatologist: a mole or spot that changes shape, color, or size; a rash that lasts more than two weeks; pain, blistering, or open sores; a butterfly-shaped flush across your face; or a vascular birthmark or growing bump in an infant. Each of these can signal something that a tube of hydrocortisone is simply not equipped to treat.

The guidance below draws on peer-reviewed research from dermatologists in the Convene directory, including specialists in melanoma detection, autoimmune skin disease, and pediatric dermatology at NYU, Penn, and Northwestern.

Why this matters

The decision to see a dermatologist often hinges on a simple question: could this be something serious? Over-the-counter creams cover a narrow range of problems — contact dermatitis, mild eczema, basic fungal infections. They do not treat skin cancers, autoimmune conditions, or vascular anomalies, and using them on those conditions can delay a diagnosis by weeks or months.

Early detection research in dermatology is consistent on one point: stage at diagnosis predicts outcome. Melanoma caught at stage I has a five-year survival rate well above 90%. Caught after it has spread to distant organs, that figure drops sharply [1][2]. The biology does not pause while you wait to see whether the cream helps.

The 5 signs

1. A mole or spot that is changing

The ABCDE rule — Asymmetry, Border irregularity, Color variation, Diameter over 6 mm, Evolution — has been the backbone of melanoma screening for decades. The most important letter is E. Any mole or dark spot that is noticeably different from how it looked six months ago deserves a dermatologist's eye, not a wait-and-see approach [1].

An updated review of the ABCDE framework published in CA: A Cancer Journal for Clinicians tracked how diagnostic tools evolved over 25 years, from physician examination alone to dermoscopy to computer-assisted analysis. The conclusion: clinical suspicion driven by the ABCDE criteria remains the first and most essential filter, regardless of which imaging tools are available downstream [1]. OTC creams have no role here.

2. A rash that hasn't improved in two weeks

Most irritant or allergic contact rashes resolve with a mild steroid cream and avoidance of the trigger within 7 to 14 days. If yours hasn't moved in that window, the diagnosis is probably wrong or there are multiple things going on. Conditions that can mimic a plain rash but require specialist care include psoriasis, tinea infections that have been inadequately treated (and may now be antifungal-resistant), early cutaneous T-cell lymphoma, and secondary syphilis.

The two-week mark is a practical threshold, not a hard biological rule. But it's the point at which continuing to self-treat without a confirmed diagnosis adds risk rather than reducing it.

3. Pain, blistering, or open sores

Blisters that form on reddened skin, especially if they spread or recur, can indicate herpes zoster (shingles), bullous pemphigoid, or — in severe cases — Stevens-Johnson syndrome. These conditions require prescription treatment and, in some cases, urgent care. Shingles responds best to antivirals started within 72 hours of rash onset; waiting for an OTC product to work exhausts that window.

Open sores that don't heal within three to four weeks on a sun-exposed area (face, ears, back of hands, lower lip) warrant evaluation for squamous cell carcinoma. UV exposure is a direct driver of these cancers, and the dose-response relationship between cumulative UV and skin cancer risk is well established in the dermatology literature [4].

4. A butterfly-shaped rash across the nose and cheeks

A red, flat or slightly raised rash that spans both cheeks and the bridge of the nose in a butterfly pattern is a classic presentation of cutaneous lupus. It can precede systemic lupus erythematosus (SLE) or occur without internal organ involvement, but either way it needs to be evaluated. SLE classification criteria developed by the Systemic Lupus International Collaborating Clinics require meeting at least four specific criteria — including at least one clinical and one immunologic finding — to confirm the diagnosis [7]. A face cream won't provide those findings.

Researchers at the University of Pennsylvania developed the CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index) specifically to capture how much of the skin is involved and how severe the damage is [6]. This kind of structured assessment requires a dermatologist or rheumatologist, and treatment for active cutaneous lupus now includes targeted biologics — including interferon-pathway inhibitors evaluated in randomized trials — that are far removed from anything available over the counter [8].

5. A vascular birthmark or growing bump in an infant

Infantile hemangiomas are common — they appear in roughly 5% of infants — but not all of them are safe to observe. Hemangiomas near the eye, airway, or in certain segmental patterns can cause permanent damage if not treated promptly. A large randomized controlled trial published in the New England Journal of Medicine established that propranolol at 3 mg/kg/day for six months is the standard treatment for hemangiomas that require intervention [9]. That decision, and the monitoring that goes with it, belongs with a pediatric dermatologist, not a parent trying products from a pharmacy shelf.

What OTC creams are actually good for

Hydrocortisone 1% cream works for mild contact dermatitis, insect bites, and minor irritation. Antifungal creams work for tinea (athlete's foot, ringworm) when applied consistently for the full course. Zinc oxide and basic emollients are useful for barrier protection. None of these address autoimmune skin disease, infections that have entered deeper tissue layers, pigmented lesions, or vascular anomalies.

Questions to ask your doctor

  • Is this rash consistent with something that responds to topical steroids, or do I need a different diagnosis first?
  • How long is a reasonable trial of OTC treatment before I should come back?
  • Does this spot or mole need a biopsy, or can we watch it?
  • I have a family history of melanoma — should I be doing skin checks on any schedule?
  • My child has a birthmark that seems to be growing. Does it need imaging or a specialist evaluation?

The bottom line

Most rashes are self-limiting and OTC creams work fine for them. The five signs above are where that changes: a changing mole, a rash that persists past two weeks, blistering or open sores, a butterfly facial rash, or a vascular anomaly in an infant. Each can be the first visible sign of something that gets harder to treat the longer it goes unrecognized. A dermatologist visit is the appropriate next step — not a second brand of cream.

Research informing this article

Peer-reviewed research from the following specialists listed on Convene informs this explainer. They did not write or review the article; their published work is cited throughout.

  • Darrell Rigel, MD

    Clinical Professor of Dermatology, Mount Sinai Icahn School of Medicine; Clinical Professor, Ronald O. Perelman Department of Dermatology at NYU Grossman School of Medicine

    NYU Langone Hospital—Brooklyn

  • Victoria Werth, MD

    Chief, Dermatology, Philadelphia V.A. Hospital; Professor of Dermatology at the Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center

    University of Pennsylvania Hospital

  • Anthony Mancini, MD

    Professor of Pediatrics and Dermatology; Head, Division of Pediatric Dermatology

    Northwestern Memorial Hospital

Sources

  1. 1.
    The Evolution of Melanoma Diagnosis: 25 Years Beyond the ABCDsCA A Cancer Journal for Clinicians, 2010. DOI
  2. 2.
    Early Detection of Malignant Melanoma: The Role of Physician Examination and Self-Examination of the SkinCA A Cancer Journal for Clinicians, 1985. DOI
  3. 3.
    Malignant melanoma in the 1990s: the continued importance of early detection and the role of physician examination and self-examination of the skinCA A Cancer Journal for Clinicians, 1991. DOI
  4. 4.
    Cutaneous ultraviolet exposure and its relationship to the development of skin cancerJournal of the American Academy of Dermatology, 2008. DOI
  5. 5.
    Trends in sun exposure knowledge, attitudes, and behaviors: 1986 to 1996\Journal of the American Academy of Dermatology, 1997. DOI
  6. 6.
    The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An Outcome Instrument for Cutaneous Lupus ErythematosusJournal of Investigative Dermatology, 2005. DOI
  7. 7.
    Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosusArthritis & Rheumatism, 2012. DOI
  8. 8.
    Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus ErythematosusArthritis & Rheumatology, 2016. DOI
  9. 9.
    A Randomized, Controlled Trial of Oral Propranolol in Infantile HemangiomaNew England Journal of Medicine, 2015. DOI

Related articles